Intellia pauses trials after serious liver event in gene therapy patient

Investing.comMonday, October 27, 2025 at 11:37:18 AM
Intellia pauses trials after serious liver event in gene therapy patient
Intellia Therapeutics has decided to pause its clinical trials following a serious liver event experienced by a patient undergoing gene therapy. This decision highlights the potential risks associated with innovative treatments and raises concerns about patient safety. The pause in trials could delay advancements in gene therapy, which has shown promise in treating genetic disorders, making it a significant moment for both the company and the field.
— Curated by the World Pulse Now AI Editorial System

Was this article worth reading? Share it

Recommended Readings
Johnson & Johnson's oral ulcerative colitis drug shows promising results
PositiveFinancial Markets
Johnson & Johnson has announced promising results from its new oral drug aimed at treating ulcerative colitis, a chronic inflammatory bowel disease. This breakthrough could significantly improve the quality of life for patients suffering from this condition, as current treatments often involve more invasive procedures. The positive outcomes from the clinical trials not only highlight the potential of this medication but also reinforce Johnson & Johnson's commitment to advancing healthcare solutions. As the demand for effective treatments grows, this development could position the company as a leader in the gastrointestinal health market.
4basebio stock soars after partner begins clinical trials with synthetic DNA
PositiveFinancial Markets
4basebio's stock has seen a significant increase following the announcement that its partner has commenced clinical trials using synthetic DNA. This development is crucial as it highlights the potential of synthetic DNA in medical applications, which could lead to groundbreaking treatments and innovations in biotechnology. Investors are optimistic about the future prospects of 4basebio, making this a noteworthy moment in the industry.
Sionna's cystic fibrosis drug candidates show promising phase 1 results
PositiveFinancial Markets
Sionna has reported encouraging results from its phase 1 trials for new drug candidates aimed at treating cystic fibrosis. This is significant as cystic fibrosis is a serious genetic disorder that affects the lungs and digestive system, and effective treatments are crucial for improving patients' quality of life. The positive outcomes from these trials could pave the way for further development and potentially offer new hope for those affected by this condition.
Actinium's ATNM-400 shows promising results in prostate cancer models
PositiveFinancial Markets
Actinium Pharmaceuticals has announced promising results for its ATNM-400 treatment in prostate cancer models, showcasing potential advancements in oncology. This development is significant as it could lead to more effective therapies for patients battling this common cancer, offering hope for improved outcomes and quality of life.
Latest from Financial Markets
Sydney Sweeney Stuns with Blonde Bob at Christy Premiere Amid Scooter Braun Romance Buzz
PositiveFinancial Markets
Sydney Sweeney made a striking appearance at the premiere of 'Christy' with her new blonde bob haircut, capturing attention not just for her style but also amid swirling rumors about her romance with Scooter Braun. This event highlights Sweeney's rising star power in Hollywood and her ability to draw media attention, making her a significant figure in the entertainment industry.
Germany in ‘dramatic’ economic decline – leading think tank
NegativeFinancial Markets
Germany is facing a 'dramatic' economic decline, according to ifo chief Clemens Fuest. After years of stagnant GDP and unsuccessful recovery attempts, the situation has become increasingly concerning. This matters because a declining economy can lead to job losses, reduced consumer spending, and overall instability in the region, affecting not just Germany but potentially the broader European economy.
Argentina’s Javier Milei hails ‘historic’ win in pivotal elections
PositiveFinancial Markets
Javier Milei's recent victory in Argentina's elections is being hailed as historic, marking a significant shift towards free-market reforms. This win has led to a surge in the country's dollar-denominated bonds, reflecting investor confidence in the new administration's economic policies. This matters because it signals a potential turnaround for Argentina's economy, which has faced numerous challenges in recent years.
Rachel Reeves says the U.K. has been successful with Trump 2.0 because they share the same ‘concerns about global imbalance’
PositiveFinancial Markets
Rachel Reeves, the Chancellor of the Exchequer, highlighted the successful relationship between the U.K. and the U.S. under Trump 2.0, emphasizing their shared concerns about global imbalance. This connection is crucial as it underscores the importance of international relationships in both business and politics, potentially leading to collaborative efforts that can address pressing global issues.
Countdown to Fed cut: Bond investors scale back on longer-dated Treasuries
NeutralFinancial Markets
As the Federal Reserve approaches a potential interest rate cut, bond investors are adjusting their strategies by scaling back on longer-dated Treasuries. This shift reflects a cautious optimism in the market, as investors anticipate changes in monetary policy that could influence yields and overall economic conditions. Understanding these movements is crucial for anyone involved in finance, as they can signal broader trends in the economy.
EastGroup Properties stock price target raised to $200 from $190 at Cantor
PositiveFinancial Markets
EastGroup Properties has seen its stock price target raised from $190 to $200 by Cantor, indicating strong confidence in the company's future performance. This adjustment reflects positive market sentiment and suggests that investors can expect continued growth, making it a noteworthy development for those tracking real estate investments.